GlassScriptPhysician profile
Lisa Jordan
NPI 1356650055
$6,642.78
in general payments reported to CMS, 2019-2025
34 companies · $2,235 in 2025
The $2,235 reported for 2025 was more than what 96% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $17.51 · 2022: $690 · 2023: $1,298 · 2024: $2,403 · 2025: $2,235.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,368 · Education: $568.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,367.60 |
| Education | $568.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,387.01 | 2022-2025 | |
| Sun Pharmaceutical Industries INC. | $1,079.38 | 2022-2025 | Ilumya, Odomzo, Blu-U |
| Janssen Biotech, INC. | $893.90 | 2021-2025 | Tremfya, Stelara, Simponi Aria |
| Genzyme Corporation | $467.76 | 2022-2025 | |
| Regeneron Healthcare Solutions, INC. | $452.60 | 2023-2025 | Dupixent, Libtayo |
| Novartis Pharmaceuticals Corporation | $289.98 | 2022-2025 | |
| Ucb, INC. | $256.78 | 2023-2025 | Bimzelx, Cimzia |
| Lilly USA, LLC | $227.71 | 2022-2025 | Ebglyss, Taltz |
| E.R. Squibb & Sons, L.L.C. | $211.06 | 2024-2025 | Sotyktu |
| Pfizer INC. | $158.49 | 2024-2025 | |
| Leo Pharma INC. | $148.63 | 2023-2025 | Adbry, Spevigo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $145.57 | 2023-2025 | Spevigo |
| Amgen INC. | $123.49 | 2023-2025 | Otezla, Otezla |
| Janssen Scientific Affairs, LLC | $87.50 | 2022 | |
| Arcutis Biotherapeutics, INC. | $82.44 | 2023-2025 | Zoryve |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Almirall LLC | $61.75 | 2022-2023 | Seysara |
| Incyte Corporation | $60.60 | 2023-2025 | Opzelura |
| Verrica Pharmaceuticals INC. | $59.85 | 2024-2025 | Ycanth |
| Genentech USA, INC. | $51.93 | 2023-2024 | Erivedge |
| Dermavant Sciences, INC. | $45.00 | 2023 | Vtama |
| Galderma Laboratories, L.P. | $37.95 | 2025 | Nemluvio |
| Biofrontera INC. | $36.55 | 2022-2025 | Ameluz |
| Organon LLC | $34.70 | 2025 | Vtama |
| Convatec INC. | $31.41 | 2025 | |
| Botanix Sb INC | $31.05 | 2025 | Sofdra |
| Chiesi USA, INC. | $23.94 | 2024 | Filsuvez |
| Vertex Pharmaceuticals Incorporated | $23.59 | 2025 | |
| Mylan Institutional INC. | $23.59 | 2023 | Hulio |
| Organogenesis INC. | $23.44 | 2023 | Puraply |
| Helsinn Therapeutics (U.S.), INC. | $22.41 | 2023 | Valchlor |
| Kerecis Limited | $20.50 | 2023 | Kerecis Omega3 Surgiclose, Kerecis Omega3 Graftguide, Kerecis Omega3 Marigen |
| Kyowa Kirin, INC. | $14.67 | 2023 | Poteligeo |
| Paratek Pharmaceuticals, INC. | $14.05 | 2024 | Nuzyra |
| Bioventus LLC | $13.50 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lisa Jordan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.